Outcomes of cardiopulmonary resuscitation in patients with pulmonary arterial hypertension
- PMID: 35514777
- PMCID: PMC9063951
- DOI: 10.1002/pul2.12066
Outcomes of cardiopulmonary resuscitation in patients with pulmonary arterial hypertension
Abstract
Over the past 20 years, despite significant advancements in pulmonary arterial hypertension (PAH) medical therapy, many patients require admission to the hospital and are at risk for in-hospital cardiac arrest (IHCA). Prior data found poor survival in PAH patients after cardiac arrest. The purpose of this study was to explore post-IHCA outcomes in PAH patients receiving advanced medical therapies. This is a single-center retrospective study of PAH patients who underwent cardiopulmonary resuscitation for IHCA between July 2005 and May 2021. Patients were identified through an internal cardiac arrest database. Twenty six patients were included. Half of the cohort had idiopathic PAH, with 54% of patients on combination therapy, 27% on monotherapy, and 19% of patients on no therapy. Mean right atrial pressure, mean pulmonary artery pressure, cardiac index, and pulmonary vascular resistance were 13 ± 6 mmHg, 57 ± 13 mmHg, 2.0 ± 0.7 L/min/m2, and 14.5 ± 7.6 Wood units, respectively. Most common etiology of cardiac arrest was circulatory collapse. Initial arrest rhythm in all but one patient was pulseless electrical activity. Six patients (23%) achieved return of spontaneous circulation (ROSC) and one patient (4%) survived to hospital discharge. Rates of ROSC and survival to discharge after IHCA are poor in patients with PAH. Even patients with mild hemodynamics had low likelihood of survival. In patients who are lung transplant candidates, there should be early consideration of extracorporeal support before cardiac arrest.
Keywords: CPR; in‐hospital cardiac arrest; pulmonary hypertension; pulseless electrical activity.
© 2022 The Authors. Pulmonary Circulation published by Wiley Periodicals LLC on behalf of the Pulmonary Vascular Research Institute.
Conflict of interest statement
Gabriel Wardi is supported by the National Foundation of Emergency Medicine and receives funding from the Gordon and Betty Moore Foundation (#GBMF9052) and the National Institutes of Health, although not related to this study. Demosthenes G. Papamatheakis has received honoraria from Janssen PH. Timothy M. Fernandes has served as consultant for Bayer and Janssen PH. Nick H. Kim has served as consultant/steering committee for Bayer, Gossamer Bio, Janssen, Merck, United Therapeutics; Speakers Bureau for Bayer, Janssen; and has received research support from Acceleron, Bellerophon, Eiger, Lung Biotechnology, and SoniVie. The remaining authors report no relevant disclosures or conflicts of interest.
Figures
References
-
- Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JS, Howard LS, Pepke‐Zaba J, Sheares KK, Corris PA, Fisher AJ, Lordan JL, Gaine S, Coghlan JG, Wort SJ, Gatzoulis MA, Peacock AJ. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med. 2012;186(8):790–6. 10.1164/rccm.201203-0383OC - DOI - PubMed
-
- Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud‐Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023–30. 10.1164/rccm.200510-1668OC - DOI - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous
